3 days ago
Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
Citi analyst Samantha Semenkow reiterated a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday and set a price target of $4.00.
Confident Investing Starts Here:
According to TipRanks, Semenkow is an analyst with an average return of -20.6% and a 26.32% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Argenx Se, Allogene Therapeutics, and Catalyst Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $8.33 average price target.
